---
schema_version: "secwatch.filing_event.v1"
accession: "0001297184-22-000053"
form_type: "8-K"
ticker: "AMPH"
cik: "0001297184"
company_name: "Amphastar Pharmaceuticals, Inc."
filed_at: "2022-11-07T23:59:59+00:00"
generated_at: "2026-06-22T05:03:43.865120+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Amphastar Q3 revenue up 7% to $120.1M; GAAP EPS falls to $0.30 from $0.59 YoY

## Summary
- Net revenues $120.1M for Q3 2022, up from $112.2M in Q3 2021 (7% growth).
- GAAP diluted EPS $0.30 vs $0.59 prior year; adjusted non-GAAP EPS $0.38 vs $0.46.
- Nine-month revenues $364.0M vs $316.9M; GAAP net income $57.5M vs $42.4M.
- Growth cited from epinephrine, Primatene Mist, and glucagon sales.
- No guidance issued; management optimistic about pipeline progress.

## SEC filing metadata
- accession: 0001297184-22-000053
- form_type: 8-K
- ticker: AMPH
- cik: 0001297184
- company_name: Amphastar Pharmaceuticals, Inc.
- filed_at: 2022-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1297184/000129718422000053/0001297184-22-000053-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1297184/000129718422000053/amph-20221107x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001297184-22-000053
- JSON: https://secwatch.observer/filing/0001297184-22-000053.json
- Plain text: https://secwatch.observer/filing/0001297184-22-000053.txt

## Key facts
- Earnings Releases
  Amphastar Pharmaceuticals, Inc. reported three months ended September 30, 2022 results: revenue $120.1 million, net income $15.9 million, EPS $0.30 per share.
  - Period: three months ended September 30, 2022
  - Revenue: $120.1 million
  - Net income: $15.9 million
  - EPS: $0.30 per share
  - Result: reported results
  source text: in such a filing. ​ --- EX-99.1 (EX-99.1) --- ​ Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 20 22 ​ Reports Net Revenues of $120.1 Million for the Three Months Ended September 30, 2022 ​ RANCHO CUCAMONGA, CA – November 7, 2022 – Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) (“Amphastar” or the “Company”) today
  evidence_url: https://www.sec.gov/Archives/edgar/data/1297184/000129718422000053/0001297184-22-000053-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.